Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E) · developed by Vir Biotechnology
VIR-5525 (AMX-525) is a protease-activated, dual-masked T-cell engager with an EGFR-binding domain and a CD3-binding domain. Masking polypeptides are released by tumor protease cleavage in the tumor microenvironment, allowing it to bind T cells and EGFR-expressing tumor cells. It is being studied in EGFR-positive solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06960395 | Phase 1 | Solid Tumor Malignancies | Recruiting | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EGFREGFR Positive Solid TumorsSolid Tumor Malignancies
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →